Bio-Rad (BIO) Q2 2025 Earnings Call Transcript

Motley Fool Transcribing, The Motley Fool

Mon, May 4, 2026 astatine 9:27 AM CDT 35 min read

Image source: The Motley Fool.

DATE

Thursday, July 31, 2025 astatine 5 p.m. ET

CALL PARTICIPANTS

• Chief Executive Officer — Norman D. Schwartz

• President and Chief Operating Officer — Jonathan P. DiVincenzo

• Executive Vice President and Chief Financial Officer — Roop K. Lakkaraju

• Vice President, Investor Relations — Yong Chung

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Yong Chung: Good afternoon, everyone, and convey you for joining us. Today, we volition reappraisal the 2nd 4th 2025 fiscal results and supply an update connected cardinal concern trends for Bio-Rad. With maine connected the telephone contiguous are Norman Schwartz, our Chief Executive Officer; Jon Jonathan DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer. Before we statesman our review, I'd similar to punctual everyone that we volition beryllium making forward-looking statements astir management's goals, plans and expectations, our aboriginal fiscal show and different matters. These statements are based connected assumptions and expectations of aboriginal events that are taxable to risks and uncertainties. Our existent results whitethorn disagree materially from these plans, goals and expectations.

You should not spot undue reliance connected these forward-looking statements, and I promote you to reappraisal our filings with the SEC, wherever we sermon successful item the hazard factors successful our business. The institution does not mean to update immoderate forward-looking statements made during the telephone today. Finally, our remarks contiguous volition see references to non-GAAP financials, including nett income and diluted net per share, which are fiscal measures that are not defined nether mostly accepted accounting principles. In summation to the -- excluding definite atypical and nonrecurring items, our non-GAAP fiscal measures exclude changes successful the equity worth of our involvement successful Sartorius AG successful bid to supply investors with a amended knowing of Bio-Rad's underlying operational performance.

Investors should reappraisal the reconciliation of these non-GAAP measures to the comparable GAAP results contained successful our net release. We person besides posted a supplemental net presumption successful the Investor Relations conception of our website for your reference. With that, I'll present crook the telephone implicit to our Chief Operating Officer, Jon DiVincenzo.

Jonathan P. DiVincenzo: Thank you, Ed. Good afternoon, everyone, and convey you for joining america today. We are pleased to stock our 2nd 4th 2025 results, which bespeak coagulated execution crossed the business. Both gross and operating borderline exceeded statement expectations, underscoring the spot of our portfolio and the subject of our teams successful a challenging and rapidly evolving macroeconomic environment. Our Clinical Diagnostics concern remained stable, portion our Life Science conception benefited from the spot successful our process chromatography portfolio. Product premix and a continued absorption connected outgo power and discretionary spending helped thrust an outperformance successful operating borderline for the quarter.